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Abstract
Mammary gland development and breast cancer growth require multiple factors both of endocrine and paracrine origin. We
analyzed the roles of Epidermal Growth Factor Receptor (EGFR) and Hepatocyte Growth Factor Receptor (Met) in mammary
epithelial cells and mammary tumor cells derived from a mutated-ErbB2 transgenic mice. By using highly specific tyrosine
kinase inhibitors we found that MCF-10A and NMuMG mammary epithelial cell lines are totally dependent on EGFR
activation for their growth and survival. Proliferation and 3D-morphogenesis assays showed that HGF had no role in
maintaining mammary cell viability, but was the only cytokine able to rescue EGFR-inhibited mammary cells. Insulin-Like
Growth Factor-I (IGF-I), basic-Fibroblast Growth Factor (b-FGF) and Neuregulin, which are well known mammary
morphogenic factors, did not rescue proliferation or morphogenesis in these cell lines, following EGFR inhibition. Similarly,
ErbB2-driven tumor cells are EGFR-dependent and also display HGF-mediated rescue. Western-blot analysis of the signaling
pathways involved in rescue after EGFR inhibition indicated that concomitant ERK1/2 and AKT activation was exclusively
driven by Met, but not by IGF-I or b-FGF. These results describe a unique role for EGFR and Met in mammary epithelial cells
by showing that similar pathways can be used by tumorigenic cells to sustain growth and resist to EGFR-directed anti-
tumorigenic drugs.
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Introduction
Circulating hormones like estrogen, progesterone, growth
hormone and prolactin were among the first endocrine factors
which were identified to be necessary for mammary gland
morphogenesis and differentiation during growth, reproductive
cyclicity and pregnancy [1]. Although a direct role for these
hormones is known, recent evidences show that their main
biological activities are achieved through the release of local
growth factors by mammary epithelial and stromal cells. These
factors subsequently diffuse and activate their respective receptors
in the stromal or epithelial compartments promoting an epithelial-
mesenchymal interaction. Both cellular compartments of the gland
are thus required for the correct development of this organ [2–4].
These indirect signaling mechanisms ensure that the systemic
stimulus is amplified within the target organ and that different cell
types participate in the morphogenic events in a coordinated
manner and fine-tuned according to local requirements.
Most of these locally released molecules act through specific
tyrosine kinase receptors (RTK) promoting several biological
responses, like proliferation, remodelling of the extracellular
matrix and motility of the target cells. Although some of these
factors have a precise and unique role during morphogenesis or
remodelling of the gland, many signaling pathways activated
downstream of different RTKs are identical. Thus, these pathways
may act as redundant when activated simultaneously in the same
cell type, possibly reinforcing the phosphorylation cascade and its
final biological effect.
One of the best described RTK that act as a fundamental
morphogenic modulator of the mammary gland is the Epidermal
Growth Factor Receptor (EGFR). Within the rodent mammary
gland, locally released amphiregulin, whose only known receptor is
EGFR, was found to mediate estrogen signaling during pubertal
mammary development. The steroid hormone acts by stimulating
amphiregulin release by the estrogen receptor positive epithelial
compartment of the gland. Amphiregulin then promotes EGFR
activation within the stromal compartment of the gland driving the
correct branching of this organ [5,6]. Although the main targets of
amphiregulin are stromal cells, this does not rule out that EGFR
signaling also has a role in the epithelium. EGFR is expressed in
both stromal and epithelial compartments [7,8], and other EGFR
ligands, in particular EGF, are highly expressed in the glands
during pregnancy [9]. Thus our first aim was to evaluate whether
EGFR plays a role in mammary epithelial cell growth and
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turnover. We did this by targeting this receptor with highly specific
inhibitors. The difficulty of clarifying the role of EGFR in the adult
mammary epithelial compartment is possibly due to the fact that
other receptors, with a similar expression pattern, may substitute
for the absence of EGFR or its ligands in vivo. In fact, stromal
fibroblasts produce many signals to the neighbouring epithelial
cells. Several growth factors, such as Insulin-like Growth Factor
(IGF), Fibroblast Growth Factor (FGF), Neuregulin and Hepato-
cyte Growth Factor (HGF) are expressed in the mammary stroma,
whereas their respective receptors are found in the epithelium [1].
Specifically, IGF-I has a major role in ductal morphogenesis, and
may be necessary for later stages of mammary development [10].
FGFR2 is involved in mammary development, in particular in
proliferation and invasion by terminal end buds, but seems
dispensable in the mature gland [11,12]. Neuregulin operates
during lobulo-alveolar development at pregnancy [13,14]. Finally,
the tyrosine kinase receptor for HGF, Met, was found to play a role
in mammary branching morphogenesis in ex vivo and in vitro
experiments [15,16]. Met could be a good candidate for EGFR
replacement since recent evidence has shown that this receptor
and EGFR can act cooperatively during kidney development to
regulate ureteric bud branching and mediate maintenance of the
normal adult collecting duct [17].
In this study we evaluated in mammary epithelial cell lines
whether other receptors, usually present in the mammary gland,
could sustain similar EGFR-like activities and signal transduction
pathways when EGFR signaling was ablated by administration of
highly specific inhibitors. Finally, we tested if such compensatory
mechanisms were also present in tumor cells isolated from a well
described transgenic mouse model of ErbB2 mammary tumori-
genesis.
Results
Mammary Epithelial Cells Express EGFR and Met
Receptors and Respond to HGF or EGF Treatment with
Phosphorylation of their Respective Receptors and
Activation of the ERK1/2 and AKT Pathways
We first analyzed the expression of EGFR and Met receptors
and the biochemical response to their respective ligands in 3
mammary epithelial cell lines of different origin. All cells expressed
Met and EGFR (Fig. 1A). MCF-10A and NMuMG stimulated
with HGF or EGF for 10 min, 30 min or 60 min displayed an
increase in phospho-EGFR, phospho-Met, phospho-ERK1/2 and
phospho-AKT levels that gradually returned close to basal levels
(Fig. 1B). Similar data have been already described for the BME-
UV cell line [18].
EGFR is Required for Viability of a Subset of Mammary
Epithelial Cell Lines, while Met Activation is Dispensable
To test whether EGFR or Met activity modulate viability in the
mammary cell lines we used highly specific receptor tyrosine
kinase inhibitors (RTKi; AG1478 for EGFR and PHA-665752 for
Met) at nanomolar concentrations. We first tested the specificity of
these inhibitors by stimulating serum-starved MCF-10A cells with
HGF or EGF together with AG1478 or PHA-665752 at 250 nM
(Fig. S1). Western blot analysis showed that AG1478 and PHA-
665752 inhibited exclusively the phosphorylation of EGFR and
Met respectively.
These inhibitors were then used in a viability assay to test the
dependence of different mammary cell lines on Met or EGFR
signaling (Fig. 2A). Cells, cultured in their respective growth
medium, were treated with AG1478 and PHA-665752 (250 nM)
Met and EGFR Roles in Mammary Cells
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and monitored by MTT at 24 and 48 h. All mammary epithelial
cell lines were unaffected by Met inhibitor PHA-665752. EGFR
inhibition by AG1478, did not modify BME-UV viability, while
MCF-10A and NMuMG cell viability was greatly impaired.
To determine the mechanism of viability blockade mediated by
EGFR inhibition we assayed the activation state of ERK1/2 and
AKT following AG1478 or PHA-665752 treatment in cells
cultured in proliferation medium (Fig. 2B). In response to
treatment with AG1478, but not PHA-665752, MCF-10A and
NMuMG cells showed a reduction of both ERK1/2 and AKT
phosphorylation. In agreement with the inability of the inhibitors
to reduce viability, ERK1/2 and AKT activation states were
unaltered under all conditions in BME-UV cells.
The HGF-Met Axis Restores Proliferation, Survival and
Morphogenesis in NMuMG and MCF-10A Cells Deprived
of EGFR Activity
We next examined whether Met activation could rescue cells
from growth impairment following EGFR inhibition. HGF acted
as a recovery agent in MCF-10A and NMuMG cells treated with
AG1478 (Fig. 3A). Since IGF-I, b-FGF and Neuregulin have been
described as important mediators of mammary development
[10,11,14] we tested their effect as possible alternative recovery
agents in the same cell lines. Both did not increase proliferation in
response to these growth factors following AG1478 treatment
(Fig. 3A). HGF mediated recovery in cells treated with AG1478
was evident as increased confluence in MCF-10A (that grow as
compact islands; Fig. 3B left panels) and increased cell density in
NMuMG cells (that grow as dispersed cells; Fig. 3B right panels).
NMuMG and MCF-10A cell lines possess morphogenic
capabilities when resuspended and cultured in a 3-D matrix like
collagen [16,19]. AG1478 had a dramatic effect on 3D-morpho-
genesis of both cell lines, inducing death of all cells (Fig. 3C, AG
and Video S1). HGF was the only tested growth factor able to
recover cells from EGFR inhibition (Fig. 3C, AG+HGF and Video
S2). EGF, IGF-I, b-FGF and Neuregulin were unable to recover
cell death following AG1478 treatment (not shown). Met
specificity to HGF recovery in MCF-10A and NMuMG cells
was confirmed using the highly specific Met inhibitor PHA-
665752 at 250 nM together with AG and HGF. In the presence of
this RTKi, HGF lost its capacity to recover mammary cells from
EGFR inhibition (Fig. S2, A+P+H).
Cells cycle analysis by FACS showed that EGFR inhibition led
to an increase in the percentage of cells in G0/G1 phase (Fig. 3D;
AG). HGF treatment reversed the percentage of cells in G0/G1
phase to control values (Fig. 3D; AG+HGF).
HGF is a Survival Factor in Mammary Tumor Cells Derived
from a Constitutively Activated ErbB2 Transgenic Mice
We tested whether the effects discovered in normal mammary
cells could be applied to cells isolated from a well described model
of mutated-ErbB2 transgenic mice (MMTV-neu; [20]). We first
visualized, by western-blot analysis, the presence of ErbB2, EGFR
Figure 1. Expression and activation of EGFR and Met in
mammary epithelial cells. A. Western-blot analysis of EGFR and
Met expression in human MCF-10A, murine NMuMG and bovine BME-
UV mammary epithelial cells. Mouse liver extract was used as a positive
control for both Met and EGFR. B. Western-blot analysis of EGFR, Met,
ERK1/2 and AKT phosphorylation in MCF-10A and NMuMG cells
cultivated in serum-starving medium and treated with EGF or HGF
(20 ng/ml) for 10, 30 and 60 min. EGFR, Met, ERK1/2 and AKT were used
to show comparable loadings between the lanes.
doi:10.1371/journal.pone.0044982.g001
Met and EGFR Roles in Mammary Cells
PLOS ONE | www.plosone.org 3 September 2012 | Volume 7 | Issue 9 | e44982
and Met in mammary tumor lysates obtained from different mice
(Fig. 4A). Primary cells obtained from these tumors underwent cell
death following 72 h treatment with AG1478 (250 nM) while
PHA-665752 (250 nM) had no effect (Fig. 4B). In order to test
whether AG1478-induced cell death could be recovered by Met
activation, cells treated with AG1478 were supplemented with
HGF. Cell viability reverted to control values, while supplemen-
tation of IGF-I, b-FGF and Neuregulin had no effect (Fig. 4C).
Cell cycle analysis by propidium-iodide staining and flow
cytometry showed an increase of cells in the G0/G1 phase after
AG1478 addition (Fig. 4D, AG). Following HGF treatment cells
reverted to values similar to untreated cells (Fig. 4D; AG+HGF).
To confirm Met contribution to the recovery mechanism we used
PHA-665752 together with AG and HGF. We found that in
presence of this Met TKi, HGF lost its capacity to recover ErbB2
tumor cells from EGFR inactivation (Fig. S3A; A+P+H). To
further confirm the specificity of AG1478, we treated these cells
with two other EGFR inhibitors used in clinical protocols (Iressa
and Tarceva; 1 mM). HGF retained the ability to recover ErbB2
tumor cells treated with Iressa and Tarceva (Fig. 4E and Fig. S3B).
Therefore ErbB2 tumor cells obtained from this transgenic model
are dependent on activated EGFR for growth and survival and
can be rescued by Met activation.
Met Phosphorylation Simultaneously Activates ERK1/2
and AKT when EGFR Signaling is Inhibited: Relative
Importance of the ERK1/2 and AKT Pathways for
Proliferation and 3D Morphogenesis
To understand the mechanism of recovery mediated by HGF,
we performed western-blot analysis of the phosphorylated EGFR,
Met and their downstream effectors ERK1/2 and AKT (Fig. 5A).
For this purpose serum-starved MCF-10A and NMuMG cells
were treated with EGF (10 ng/ml), HGF (20 ng/ml) or IGF-I
(100 ng/ml) in the absence or presence of AG1478.
All growth factors activated both the ERK1/2 and the AKT
pathways in the absence of EGFR inhibition (Fig. 5A, lanes 3, 5,
7). Following AG1478 treatment, HGF remained the only
cytokine able to maintain both pathways active simultaneously,
in agreement with the fact that phospho-Met is still present in
EGFR inhibited cells (Fig. 5A, lane 6). Although IGF-I-activated
phospho-AKT levels were unaffected by AG1478, phospho-
ERK1/2 levels were abolished by EGFR inhibition (Fig. 5A, lane
8; see discussion). Therefore HGF-mediated rescue of proliferation
and morphogenesis in mammary cells possibly needs simultaneous
reactivation of both the ERK1/2 and AKT pathways.
Similar western blot analyses performed on serum-starved
ErbB2 tumor cells showed basal phospho-EGFR, phospho-
ERK1/2 and phospho-AKT levels that were abolished by
AG1478 treatment. Analogously to normal mammary cells,
HGF only had the ability to restore simultaneously ERK1/2
and AKT phosphorylation in presence of EGFR inhibition. Thus
ErbB2-driven tumor cells possibly use a mechanism of recovery
comparable to that found in non malignant NMuMG and MCF-
10A cells (Fig. 5A, ErbB2). To further confirm the specificity of
AG1478, western-blot experiments were repeated using Iressa
(1 mM) in NMuMG and ErbB2-driven cells, with comparable
results (Fig. S4A).
Since EGFR and Met seem to act through similar downstream
effectors, we tested whether EGF and HGF simultaneous
treatment could increase mammary cells growth, scatter and
morphogenesis. Cells treated simultaneously with the two
cytokines displayed an increase in confluence percentage (MCF-
10A cells; Video S3 and Fig. S4B), scatter and morphogenesis
(NMuMG cells; Figure S4C) relative to EGF only or HGF only
treated cells.
We finally analyzed the relative importance of the ERK1/2 and
AKT pathways during proliferation and morphogenesis in EGFR
inhibited mammary cells (Fig. 5B). For this purpose we selectively
inhibited ERK1/2 and/or AKT pathways with UO126 15 mM
and Wortmannin 100 nM respectively. Such inhibitors were
coupled with AG1478 treatment in order to understand whether
HGF retained the ability to recover growth in mammary cells
lacking these pathways. Inhibition of the ERK1/2 and PI3K-AKT
pathways, separately and together with EGFR blockade, lead to
a decrease in cell viability. Interestingly, under all inhibitory
conditions, HGF increased cell numbers, albeit with different
efficiencies according to treatment. This behaviour indicates that
in the absence of any combination of EGFR/ERK1-2/AKT
signaling, Met still enhances proliferation in 2D cultured cells
(Fig. 5B upper panel and Fig. S5) probably activating alternative
signaling pathways.
An analysis performed on NMuMG cells grown in 3D-collagen
suspensions (Fig. 5B lower panel) gave us different results and
showed that ERK1/2 signaling was always necessary to sustain
viability: HGF supplementation could not restore viability in
UO126 treated cells (UO; UO+HGF; AG+UO; AG+UO+HGF).
On the other hand, inhibition of the PI3K-AKT signaling
pathway stopped ductal elongation but did not kill cells (WORT).
HGF addition restored growth and morphogenesis
(WORT+HGF) in Wortmannin treated cells. Interestingly, when
EGFR inhibited cells were simultaneously treated with Wortman-
nin, HGF could not act as a recovery agent (AG+WORT and
A+W+HGF). These data indicate that in the absence of EGFR
signaling the ERK1/2 and the PI3K-AKT pathways are both
independently necessary for growth in a 3-dimensional matrix but
not in a 2D proliferation assay.
Discussion
Organ growth, homeostasis of normal tissues and tumor
development may share common biological pathways. In this
study we have addressed the relationship between EGFR and Met
signaling pathways in normal mammary epithelial cells as well as
in cells derived from a well described transgenic model of
mammary tumorigenesis. We found that 2 out of 3 tested
mammary epithelial cell lines, the murine NMuMG and the
human MCF-10A cell lines, are dependent on EGFR activity in
order to grow in a 2D proliferation assay and to survive in a 3D-
morphogenesis assay. A fundamental role for the EGF receptor in
mammary gland morphogenesis has been found during pre-
pubertal growth in the stromal compartment of this organ [5,21],
but, as of now, there is no known function for this receptor in the
epithelial compartment of the adult mammary gland. Here we
described that EGFR is fundamental for growth and viability in
specific non-tumorigenic mammary cell lines that have been
obtained from adult mammary tissues. Impairment of the EGFR,
Figure 2. MCF-10A and NMuMGmammary epithelial cells show
EGFR dependence. A: MTT assay of MCF-10A, NMuMG and BME-UV
cells at 0 h, 24 h and 48 h. Cells were cultivated in their growth medium
(see materials and methods) and either left untreated (Ctrl) or treated
with PHA-665752 (PHA) or AG1478 (both 250 nM). MTT value at 0 h was
set to 100%. Columns, mean (n = 6); bars, S.E.M. *P,0.01. B. Western-
blot analysis of ERK1/2 and AKT phosphorylation in mammary cells
cultivated in their respective growth medium without (Ctrl) or with the
RTK inhibitors (250 nM, 1 h) PHA-665752 (PHA) or AG1478 (AG). EGFR,
Met, ERK1/2 and AKT were used to show comparable loadings between
the lanes.
doi:10.1371/journal.pone.0044982.g002
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but not Met signaling in these cell lines disrupted morphogenesis
and induced complete cell death. MCF-10A dependence on
EGFR may be due to these cells being cultured in an EGF
containing medium. A possible explanation for EGFR addiction in
NMuMG cells is that this cell line produces its own EGFR ligands.
In fact we found high levels of amphiregulin mRNA expression in
NMuMG cells (data not shown) possibly driving proliferation by
an autocrine loop. Other mammary epithelial cells have been
shown to produce and release EGFR ligands [22], therefore this
mechanism of growth may be common to epithelial cells even in
the adult mammary gland. The fact that BME-UV bovine
mammary cells did not respond to EGFR inhibition is probably
due to the fact that this cell line maintains the ERK1/2 and AKT
pathways active under AG1478 treatment. One possible explana-
tion is that, during the process of immortalization, inactivation of
important tumor suppressors (like PTEN) have brought BME-UV
cells to constitutively activate these fundamental signaling path-
ways. Another speculative hypothesis is that in bovines, that are
not prone to develop mammary cancers, these pathways have
constitutively higher phosphorylation levels even in non-tumori-
genic cell lines. The difference in EGFR sensitivity found in cell
lines, poses the question whether some mammary cells belonging
to different compartments of the gland (e.g. basal or luminal) may
have different requirements for growth. Expanding our research
with other mammary cells lines of different origin may clarify this
doubt. This fact is also important because tumors that arise from
cells of a particular compartment may show different responses to
specific inhibitors.
Although Met was dispensable for growth in all tested cell lines,
HGF was the only cytokine able to recover proliferation and
morphogenesis in EGFR inhibited cells. Some authors have
described a direct role for HGF in the mammary gland [23,24],
but complete data that clarify the role that Met receptor plays in
vivo are still lacking. Our laboratory is currently evaluating the role
of Met by gene targeting with mammary specific promoters
(MMTV-cre and Wap-cre), but coherently with the in vitro data
here presented, we haven’t yet found a role for the HGF receptor
in these transgenic models (manuscript in preparation). Interest-
ingly, other growth factors (IGF-I, b-FGF and Neuregulin), that
have been described as important mediators of mammary
morphogenesis [10–14,25], were unable to act as recovery agents
in these cells. We cannot exclude that these factors may play an
important role in cells derived from different mammary gland
subpopulations or breast cancers. Recent evidence shows that
EGFR may play a significant role in some HGF/Met mediated
biological responses of mammary tumor and epithelial cells. In this
system inhibition of the EGFR kinase with gefitinib or erlotinib
abolished HGF induced proliferation and motility of some
carcinoma cells [26]. On the contrary in our experimental settings
Met was able to act as a recovery agent in EGFR inhibited cells
and phospho-Met and phospho-EGFR seemed to be activated, at
least in part, separately. Although we cannot rule out a certain
degree of Met-EGFR transactivation in our system, most of the
downstream signaling is evoked by an independent, EGFR-driven
or Met-driven mechanism. The difference in the results may
depend on the different cell lines that where used or their culture
condition (we always used complete growth medium with serum
and growth factors for most of the experiments). This result
indicates how two specific pathways that originate from different
receptors may drive similar cellular responses (e.g. viability or
proliferation) independently of each other.
We also found that the synchronous activation of EGFR and
Met increased growth, scatter and morphogenesis in NMuMG
and MCF-10A cells. This effect, in which two separate tyrosine
kinase receptors may act in a redundant and additive fashion to
promote cell growth, is not unique to mammary cells. In vivo,
during kidney morphogenesis, Met tissue specific knock-outs have
reduced final nephron number. Crossing these mice with waved-2
spontaneous mutants, carrying a single point mutation that
reduces EGFR kinase activity, affects ureteric bud branching as
well as final glomerular number [17]. We recently showed that
a similar mechanism of EGFR/Met redundancy happens also in
the mammary gland [27].
ErbB2 is an important initiator of mammary tumorigenesis with
more than 30% human breast cancers exhibiting ErbB2 ampli-
fication and overexpression [28]. EGFR is often a dimerization
partner for ErbB2 both physiologically, during mammary gland
development [13,29], and pathologically in ErbB2 driven tumors
[30]. We thus evaluated the effects of EGFR inactivation in a well
described transgenic model of mammary tumorigenesis. This
transgenic line expresses an MMTV promoter-driven rat-ErbB2
carrying a mutation that forces constitutive activation of the
receptor [20]. All tumors obtained from ErbB2 mutated mice
showed EGFR, ErbB2 and Met expression. EGFR inhibition
caused death of primary and immortalized cells isolated from this
tumor. Since EGFR inhibition by AG1478 at the concentration
used in our assays is selective (IC50 3 nM; ErbB2 IC50 is
.100 mM) the ErbB2 mutation possibly activates EGFR through
hetero-dimerization. In fact we observed a decrease of both
phospho-EGFR and phospho-ErbB2 (not shown) in ErbB2 tumor
cells upon treatment with AG1478. Therefore we found that in
this transgenic model, ErbB2 activation that drives tumor growth
is coupled to EGFR kinase activity, which is fundamental for cell
viability. HGF treatment rescued EGFR inhibited tumor cells,
indicating that pathways similar to those present in the NMuMG
and MCF-10A mammary cells may also be used by cancer cells to
sustain their growth. The fact that tumor cells respond to HGF
with increased proliferation and survival following EGFR in-
hibition has also been addressed in non-small cell lung cancer
(NSCLC). A subset of NSCLC patients that develop resistance to
EGFR inhibitors show increased HGF levels supporting a role for
stromal derived HGF in promoting drug resistance [31,32]. This
type of resistance, in which normal receptor levels are accompa-
nied by a higher expression of its respective growth factor in the
surrounding stroma, may thus represent a mechanism used by
tumor cells to escape RTKi treatment. Our findings on HGF-
mediated recovery, extend the previously published results to
mammary epithelial cells and ErbB2 mammary tumor cells,
Figure 3. HGF act as a recovery agent in EGFR inhibited mammary epithelial cells. A. Viable cell count by trypan-blue exclusion staining at
48 h of MCF-10A (left panel) and NMuMG (right panel) cells cultivated in their respective growth medium and treated with the indicated factors (HGF
10 ng/ml (H), IGF-I 100 ng/ml (I), b-FGF 20 ng/ml (F), Neuregulin 20 ng/ml (N); AG1478 250 nM (A)). Untreated control (Ctrl) was set to 100%.
Columns, mean (n = 6); bars, S.E.M. *P,0.05. B. MCF-10A cells (left panels; composite of 9 fields) and NMuMG cells (right panels) cultivated in their
respective growth medium for 24 h with the indicated factors (HGF 10 ng/ml; AG1478 250 nM). Bar = 1000 mm. C. Extended death of field composite
image obtained from multiple Z-stacking pictures of MCF-10A cells (left panels) and NMuMG cells (right panels) grown in collagen for 4 days with the
indicated factors (HGF 10 ng/ml; AG1478 250 nM). Bar = 500 mm. D. Cell cycle distribution examined by propidium iodide staining and FACS analysis
of MCF-10A cells (left panels; 8 h) and NMuMG cells (right panels; 16 h) cultivated in growth medium and treated with the indicated factors (HGF
10 ng/ml, AG1478 250 nM).
doi:10.1371/journal.pone.0044982.g003
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emphasizing the fact that molecular events present in non
tumorigenic cells could be retained during tumor growth and
become the basis for drug resistance.
One of the possible mechanisms underlying mammary cell
recovery by HGF treatment following EGFR inactivation was the
ability of this cytokine to activate both the ERK1/2 and the AKT
Figure 4. HGF is a survival factor of EGFR inhibited ErbB2 mammary tumor cells. A. Western-blot analysis of ErbB2, EGFR and Met
expression in mammary tumors obtained from three separate transgenic ErbB2 mutated mice (see materials and methods). Tubulin was used as an
internal loading control. B. Phase contrast images of primary cells from ErbB2 mammary tumors (bar = 500 mm). Cells were grown in proliferation
medium and either left untreated (Ctrl) or treated with AG1478 (250 nM) or PHA-665752 (250 nM) for 96 h. C. Viable cell count by trypan-blue
exclusion staining at 48 h, of immortalized ErbB2 tumor cells treated with the indicated factors (HGF 10 ng/ml (H), IGF-I 100 ng/ml (I), b-FGF 20 ng/ml
(F), Neuregulin 20 ng/ml (N); AG1478 250 nM (A)). Untreated control (Ctrl) was set to 100%. Columns, mean (n = 6); bars, S.E.M. *P,0.05. D. Cell cycle
distribution examined by propidium iodide staining and FACS analysis of ErbB2 mammary tumor cells cultivated in growth medium and treated with
the indicated factors for 16 h (HGF 10 ng/ml, AG1478 250 nM). E. Immortalized ErbB2 tumor cells cultivated in their respective growth medium for
48 h with the indicated factors (HGF 10 ng/ml; AG1478 250 nM; IRESSA 1 mM; TARCEVA 1 mM). Bar = 500 mm.
doi:10.1371/journal.pone.0044982.g004
Met and EGFR Roles in Mammary Cells
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pathways. Thus we investigated the relative importance of these
two pathways in driving the resistance to EGFR inhibition. Our
results show that HGF was the only cytokine with the capacity to
activate the ERK1/2 and the AKT pathways independently of
EGFR signaling. Confirming the observations made by other
authors [33–35], who demonstrated that knockdown or blockade
of EGFR blocked the IGF-I-induced MAPK (suggesting that IGF-
I receptor may act upstream of EGFR) we found that IGF-I could
Figure 5. HGF activates Met, ERK1/2 and AKT in EGFR inhibited mammary cells: roles for ERK1/2 and AKT pathways. A. Western-blot
analysis of the EGFR, Met, ERK1/2 and AKT phosphorylation status in MCF-10A and NMuMG cells and ErbB2 tumor cells cultivated in starving medium
for 16 h and then treated with the RTK inhibitors AG1478 (250 nM, 1 h) before adding the indicated cytokines (10 min; EGF 10 ng/ml, HGF 10 ng/ml,
IGF-I 100 ng/ml). B. Viable cell count by trypan-blue exclusion staining at 48 h of NMuMG cells cultivated in growth medium and the indicated
inhibitors (AG/A=AG1478 250 nM; UO/U=UO126 15 mM; WORT/W=wortmannin 100 nM) in presence or absence of HGF 10 ng/ml (H). Untreated
control (Ctrl) was set to 100%. %. Columns, mean (n = 6); bars, S.E.M. *P,0.05. C. Representative pictures of NMuMG cells grown in collagen gels for 4
days in growth medium with the indicated factors (concentrations as in B; bar = 250 mm).
doi:10.1371/journal.pone.0044982.g005
Met and EGFR Roles in Mammary Cells
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not rescue the ERK1/2 pathway, but could rescue the AKT
pathway in all EGFR inhibited cell lines. In line with its inability to
rescue EGFR inhibited cells, basic-FGF was unable to activate
neither the ERK1/2 nor the PI3K-AKT pathway in the NMuMG
and MCF-10A cell lines (data not shown). Moreover both these
cell lines did not increase proliferation following b-FGF or
Neuregulin treatment. Thus, it is possible that b-FGF and
Neuregulin were not functional in our cellular model, eventually
for the lack of their respective receptors, identifying mammary cell
lines with different growth factor requirements. Alternatively,
some signaling molecules that are activated exclusively down-
stream EGFR or Met, but not by other growth factors, might
contribute to the recovery mechanism. Breast tumor kinase (Brk)
and ERK5 were recently shown to act as important mediators of
migration in breast cancer cells downstream the EGF and the
HGF receptors [36]. We are currently evaluating what is their role
in our model.
The PI3K-AKT pathway plays a fundamental role in glioblas-
toma multiforme and small cell lung cancer. In these tumors
redundant inputs provided by multiple RTKs drive signaling,
growth and survival by maintaining a robust AKT activation
[37,38]. 2D proliferation assays showed that in the absence of
EGFR inhibition, lack of activation of the ERK1/2 pathway led to
a strong decrease in cell growth while impairment of the AKT
pathway reduced cell numbers less efficiently, except in ErbB2
tumor cells. HGF treatment recovered cells in which ERK1/2
and/or AKT pathways were inhibited. When EGFR was
simultaneously inactivated, HGF was still able to recover cell
viability. Interestingly, addition of HGF recovered to almost
control levels ErbB2 cells with EGFR and AKT simultaneously
inhibited. Moreover, in the absence of EGFR signaling, activation
of the AKT pathway alone, which is highly phosphorylated
downstream of the IGF-I receptor, did not lead to growth
recovery. Thus, in this 2D proliferation model, the ERK1/2 but
not the AKT pathway, played a major, but not exclusive, role in
proliferation.
3D-morphogenesis assays, which might best recall the physio-
logical environment of mammary growth, provided us with
interesting, although different, data. ERK1/2 were still the
predominant kinases to sustain cell viability: inhibiting their
activation by UO126 induced cell death and could not be
recovered in the presence of HGF treatment. Therefore, in this
assay, other parallel pathways (like the Brk/ERK5 pathway)
cannot replace ERK1/2. On the other hand, AKT inhibition
blocked basal branching and was recovered by Met activation, but
when EGFR was coupled to AKT inhibition no recover was
possible. Therefore, in these assays, HGF-mediated recovery
following EGFR inhibition could only work if both the AKT and
ERK1/2 kinases were simultaneously active and disrupting any of
these signaling adaptors lead to cell death.
Despite the survival gains provided by anti-HER2 therapies,
patients with advanced HER2+ breast cancer frequently display
drug resistance. Often resistance occurs when mammary tumor
cells alter some important cellular pathways, including hyperacti-
vation of the PI3K-AKT or ERK pathways [39,40]. Here we have
shown that non-tumorigenic and tumorigenic mammary cells may
use HGF to promote growth in the absence of EGFR signaling.
Given that HGF, a cytokine produced by the mammary stroma, is
induced by estrogen, a systemic hormone commonly produced
during every estrous/menstrual cycle [41], this mechanism of
resistance may represent an important escape to HER2 directed
therapies.
The fact that initiation, maintenance and spread of cancer may
require molecular events analogous to the ones that are active
during physiological organ growth and remodelling is intriguing.
The study of these pathways in the normal tissue may provide
useful information for the treatment of the malignant reversion
and may potentially affect the correct regimen in patients treated
with tyrosine kinase inhibitors.
Materials and Methods
Reagents
All reagents, unless specified, were from Sigma–Aldrich (St.
Louis, MO, USA); recombinant HGF, EGF, Insulin-Like Growth
Factor I (IGF-I), Neuregulin and basic-Fibroblast Growth Factor
(bFGF) were from Immunotools (Friesoythe, Germany) and were
resuspended in PBS; AG1478, Gefitinib (Iressa), Erlotinib
(Tarceva), UO126 and Wortmannin were from LC Laboratories
(Woburn, MA, USA) and were resuspended in DMSO; PHA-
665752 was from Tocris Bioscience (Ellisville, MI, USA); DC
Protein Assay was from Bio-Rad Laboratories (Hercules, CA,
USA); Hybond enhanced chemiluminescence (ECL) nitrocellulose
membrane and Hyperfilm ECL were from GE Healthcare Bio-
Sciences (Piscataway, NJ, USA); Super Signal West Pico
Chemiluminescent Substrate was from Pierce (Rockford, IL,
USA); Collagen type I was from BD Biosciences (Bedford, MA,
USA). MTT colorimetric assay for cell proliferation was from
Upstate (Temecula, CA, USA).
Antibodies
Anti-Met mouse monoclonal antibody was from Zymed
(1:1000; South San Francisco, CA, USA); anti-EGFR rabbit
polyclonal antibody was from Santa Cruz Biotechnology (1:1000;
SC-03; Santa Cruz, CA, USA); anti-a-tubulin (1:5000) and anti-
phospho-ERK1/2 (1:5000; M 8159) mouse monoclonal antibodies
were from Sigma–Aldrich; anti-ERK1/2 mouse monoclonal was
from Upstate (1:1000; MK12; Temecula, CA, USA); anti-
phospho-Met rabbit polyclonal (tyr-1234/1235; 1:1000), anti-
phospho-AKT mouse monoclonal (ser-473; 1:1000), anti-AKT
rabbit polyclonal and anti-ErbB2 rabbit polyclonal antibodies
were from Cell Signaling Technologies (Danvers, MA,USA).
Cell Culture
MCF-10A non-tumorigenic human breast epithelial cells were
purchased from the American Type Culture Collection (ATCC
number CRL-10317; ATCC, Rockville, MD) and were grown in
DMEM/F-12 media supplemented with cholera toxin (100 ng/
ml), insulin (10 mg/ml), hydrocortisone (0.5 mg/ml), EGF (20 ng/
ml) and 5% horse serum (Euroclone, Pero, Italy). NMuMG
murine mammary epithelial cell line (ATCC number CRL-1636)
was kindly provided by R. Montesano (University of Geneva
Medical School, Switzerland) and cultured in DMEM supple-
mented with 10% FBS. BME-UV bovine mammary epithelial cell
line was isolated and kindly provided by I. Politis (Agricultural
University of Athens, Athens, Greece; [42]). BME-UV cells were
grown in DMEM, supplemented with 10% FBS (Euroclone).
Mouse liver extracts and ErbB2 primary cells and cell lines were
obtained from lobular carcinomas arising in BALB/c transgenic
mice harbouring a mutated rat Her-2/neu oncogene under the
MMTV promoter [20]. Rat ErbB2 transgenic mice were bred by
Biogem IRGS (Ariano Irpino, Italy), maintained in the transgenic
unit of the Molecular Biotechnology Center (University of Torino)
under a 12-hour light-dark cycle, and provided food and water ad
libitum. Mice were treated in conformity with European laws and
policies [43], and this study was approved by the Ethical
Committee of the University of Torino. Briefly, fresh tissue
(1:2 w/v) obtained by tumor dissection and mincing, was added to
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a 1:1 v/v mixture of DMEM/F12 medium supplemented with 2%
w/v bovine serum albumin (BSA, Fraction V), 300 U/ml
collagenase, 100 U/ml hyaluronidase, 100 U/ml penicillin,
100 mg/ml streptomycin (STEMCELL Technologies, Vancouver,
BC, Canada) and placed in a shaking incubator at 37uC overnight.
Epithelial cell aggregates obtained by centrifugation at 80 g for 30
seconds were washed in fresh DMEM/F12 medium for 3 times.
Aggregates were incubated with a 0.5 mg/ml trypsin solution
supplemented with 0.2 mg/ml EDTA followed by vigorous
pipetting for 4 minutes and subsequent washing in Hank’s
balanced salt solution (HBSS, STEMCELL Technologies) supple-
mented with 2% FBS. Cells were then treated for 3 min with
5 mg/ml dispase and 100 mg/ml DNAseI (STEMCELL Tech-
nologies) and passed through a 40 mm cell strainer (BD
Biosciences, San Jose, CA, USA) to remove remaining cell
aggregates. ErbB2 cells were then cultured in DMEM supple-
mented with 10% FBS, 10 000 U penicillin G (Euroclone) and
10 mg/ml streptomycin (Euroclone). Cells were maintained in
a 5% CO2–water-saturated atmosphere and routinely passaged
every 2–3 d by washing with PBS followed by trypsinization.
Western Blot Analysis
For western-blot, all cell lines were seeded in six-well plates and
allowed to grow to 50% confluence. If needed, cells were starved
for 24 h in medium with no serum and 0.4% BSA. The indicated
cytokines were added for the indicated time intervals. UO126
(15 mM), Wortmannin (100 nM), PHA-665752 (250 nM),
AG1478 (250 nM), Iressa (500 nM) were resuspended in dimethyl
sulfoxide (DMSO) in 10 mM stock solution and added 1h before
lysis or the indicated treatments. Control samples were added with
an equivalent amount of DMSO. Cells were washed with ice-cold
PBS, lysed, and scraped in lysis buffer (20 mM Tris (pH 7.5),
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
1 mM h-glycerolphosphate) with Protease Inhibitor Cocktail
(1:100) and 1 mM sodium orthovanadate. Protein lysates
(20 mg) were cleared of cellular debris by centrifugation at 4uC
for 10 min at 12 000 g, quantified using DC Protein Assay,
resolved in 10% SDS-PAGE gels, and transferred to Hybond-C
Extra nitrocellulose membranes. After the transfer of proteins, the
membranes were blocked at room temperature for 2 h with Tris-
buffered saline (TBS, 10 mM Tris and 150 mM NaCl, pH 7.4)
containing 10% BSA and then incubated overnight at 4uC with
the appropriate primary antibodies. The membranes were washed
six times for 5 min each in TBS–Tween and then incubated for
1 h at room temperature with HRP-conjugated secondary
antibodies. The membranes were again washed six times in
TBS–Tween and incubated for 5 min at room temperature with
Super Signal West Pico ECL chemiluminescent substrate. The
proteins were visualized by briefly exposing the membrane to an
autoradiographic Hyperfilm ECL.
MTT Cell Proliferation Assay
For MTT cell proliferation assay, MCF-10A, NMuMG and
BME-UV cell lines were seeded in 96-well plates at low density
and allowed to grow overnight. At 0 h the medium was removed
and replaced with medium containing the indicated cytokines. Cell
proliferation was evaluated at the indicated times using the MTT
assay following the manufacturer’s instructions. Briefly, the
intensity of the coloured compound formed (formazan dye) was
quantified with an ELISA microplate reader. When MTT reagent
was added the wells were subjected to further incubation for
a period of 4 h to facilitate the reaction between mitochondrial
dehydrogenase released from viable cells and tetrazolium salt of
MTT reagent. The absorbance was measured at 550 nm, with the
reference at 650 nm. Cell viability of cells at 0 h was set to 100%.
Each experiment was repeated three times independently and in
each experiment each treatment was performed with six replicate
culture wells.
2D Growth Assay
Cells were seeded in six well plates at a density of 16105 cells
per well and allowed to grow. After 24 h, the medium was
removed and replaced with fresh medium containing the indicated
factors and/or inhibitors. After 24–48 h cells were photographed
with a Leica AF6000 LX (Leica Microsystems, Wetzlar, Germany)
inverted microscope equipped with a Leica DFC350FX digital
camera and a motorized stage controlled by the LAS AF software
(Leica Microsystems, Wetzlar, Germany). Images of multiple fields
were captured using the Tile Scan feature for automatic scanning
(363 fields). Tile Scan image capture and merging was used to
provide a single panoramic view at 50x magnification. For Video
S3, MCF-10A cells cultivated in DMEM/F12 medium (5% horse
serum without growth factors) for 16 h and photographed at
5 min intervals for 2 d. The video was edited using Wax (freeware
video editing software http://www.debugmode.com/wax/; ac-
cessed August 2011).
Trypan Blue Viability Assay
Cells were seeded in six well plates at a density of 16105 cells
per well and allowed to grow. After 24 h, the medium was
removed and replaced with medium containing 10% FBS and the
indicated cytokines. Cell proliferation was evaluated after 48 h by
trypsinization, resuspension in PBS, colouring with trypan blue
(0.1%) and counting on Burker chambers. Nonviable, blue
coloured cells, were excluded. Untreated control samples (Ctrl)
were set to 100%. Each experiment was repeated three times
independently, and in each experiment, each treatment was
performed with two replicate culture wells.
Cell Cycle Analysis
For cell cycle analysis cells were seeded in six-well plates in their
respective growth medium and allowed to grow to 50% confluence
then the indicated factors and/or inhibitors were added for 16 h.
Cells were trypsinized and washed with PBS, then treated with
RNAse (0.25 mg/ml) and stained with propidium iodide (50 mg/
ml). The cell cycle distribution in G0/G1, S, and G2/M phases
was calculated using the CellQuest program (BD Biosciences).
Each experiment was repeated three times independently, and
within each experiment, each treatment was performed with two
replicate culture wells.
Morphogenesis Assay
The morphogenesis assay was performed as described in [44].
Briefly, cells were trypsinized and washed with PBS. 56103 cells
were embedded in 0.5 ml collagen gels. After the collagen solution
gelled (37uC, 15 min), 1 mL of complete medium was slowly
added to each well. After 48 h of growth the indicated factors were
added and the cultures incubated at 37uC for 4 d and
photographed with a Leica AF6000 LX inverted microscope.
Frames taken from multiple Z-stacks were recomposed on a single
picture using the extended depth of field freeware software,
Combine Z from Alan Hadley (http://hadleyweb.pwp.
blueyonder.co.uk/; accessed August 2012). For Video S1 and
S2, NMuMG cells stably expressing EGFP, were embedded in
collagen gels, cultivated for 3 d and then treated with the indicated
factors/inhibitors. Cell were photographed at 30 min intervals for
2 d and the video was edited using Wax software.
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Statistical Analysis
Experimental data are presented as mean6sem. Statistical
differences between treatments were calculated with one-way
ANOVA using the Statgraphics package (STSC Inc., Rockville,
MD, USA). When significant differences were found, means were
compared by an unpaired Student’s t-test.
Supporting Information
Figure S1 Western-blot analysis of the EGFR and Met
phosphorylation. MCF-10A cells were cultivated in starving
medium for 16 h, then treated with the indicated RTK inhibitors
for 45 min (PHA-665752, PHA, Met inhibitor; AG1478, AG,
EGFR inhibitor; 250 nM) and finally with EGF or HGF for
10 min (10 ng/ml).
(TIF)
Figure S2 Viable cell count by trypan-blue exclusion
staining at 48 h of MCF-10A and NMuMG cells cultivated
in growth medium and the indicated inhibitors (AG/
A=AG1478 250 nM; PHA/P=PHA-675752 250 nM) in
presence or absence of HGF 10 ng/ml (H). Untreated
control (Ctrl) was set to 100%. Columns, mean (n= 6); bars,
S.E.M. *P,0.05.
(TIF)
Figure S3 A/B Viable cell count by trypan-blue exclu-
sion staining at 48 h of ErbB2 tumor cells cultivated in
growth medium and the indicated inhibitors (AG/
A=AG1478 250 nM; PHA/P=PHA-675752 250 nM;
IRE/I= IRESSA 1 mM; TAR/T=TARCEVA 1 mM) in
presence or absence of HGF 10 ng/ml (H). Untreated
control (Ctrl) was set to 100%. Columns, mean (n = 6); bars,
S.E.M. *P,0.05.
(TIF)
Figure S4 A. ERK1/2 and AKT phosphorylation in
starved NMuMG cells and ErbB2 tumor cells treated
with Iressa and the indicated cytokines. B. % confluence
calculated from the experiment shown in Video S3. C. 2D-growth
(upper fields) and 3D-morphogenesis (lower fields) of NMuMG
cells treated with the indicated factors (10 ng/ml).
(TIF)
Figure S5 Viable cell count by trypan-blue exclusion
staining at 48 h of MCF-10A and ErbB2 tumor cells
cultivated in growth medium and the indicated inhibi-
tors (AG/A=AG1478 250 nM; UO/U=UO126 15 mM;
WORT/W=Wortmannin 100 nM) in presence or ab-
sence of HGF 10 ng/ml (H). Untreated control (Ctrl) was set
to 100%. %. Columns, mean (n= 6); bars, S.E.M. *P,0.05.
(TIF)
Video S1 NMuMG cells stably expressing EGFP were
grown in collagen for 2 days. Cells were then treated with
AG1478 250 nM and time lapse acquisition (48 h; 100x
magnification) was made using a computer controlled Leica
AF6000LX inverted microscope equipped with a motorized stage
controlled by the LAS AF software.
(MOV)
Video S2 NMuMG cells cultured as in Video S1 were
treated with the indicated factors (HGF 10 ng/ml;
AG1478 250 nM) and time lapse acquisition was made
as in Video S1.
(MOV)
Video S3 MCF-10A cells were starved overnight in
medium containing 5% horse serum and then treated
with the indicated factors (10 ng/ml). Time lapse acquisi-
tion (6 h; 506magnification) was made using a computer




NMuMG cells were kindly provided by Roberto Montesano (University
Medical Center of Geneva, Switzerland). We are grateful to Cristina
Cecere for technical assistance.
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